Oxymorphone Extended Release Does Not Affect CYP2C9 or CYP3A4 Metabolic Pathways
Authors:
- Henry J. PieniaszekHPHenry J. Pieniaszek
- Arnold R. GammaitoniAGArnold R. Gammaitoni
- Harry AhdiehHAHarry Ahdieh
- 7 March 2005
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 45 (3) , 337-345
Abstract
Two 14‐day, randomized, open‐label, parallel‐group studies examined the effects of extended‐release (ER) oxymorphone on CYP2C9 or CYP3A4 metabolic activities in healthy subjects. On days −1, 7, and 14, subjects received either a CYP2C9 probe (tolbutamide 500 mg) or CYP3A4 probes (midazolam and [14C N‐methyl]‐erythromycin for the erythromycin breath test). Subjects were randomized to 5 groups: high‐dose oxymorphone ER (3 × 20 mg q12h) + naltrexone (50 mg q24h); low‐dose oxymorphone ER (10–20 mg q12h); rifampin (2 × 300 mg q24h), an inducer of CYP2C9 and CYP3A4 activities; naltrexone (50 mg q24h); or CYP probes alone (controls). Probe metabolism was significantly altered by rifampin on days 7 and 14 (P < .05), whereas probe metabolism was not significantly affected by low‐dose oxymorphone ER or by high‐dose oxymorphone ER plus naltrexone. Oxymorphone ER exhibits a minimal potential for causing metabolic drug‐drug interactions mediated by CYP2C9 or CYP3A4.Keywords
This publication has 8 references indexed in Scilit:
- Pharmacokinetics and Dose‐Proportionality of Oxymorphone Extended Release and Its Metabolites: Results of a Randomized Crossover StudyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2004
- Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450–metabolized drugsThe American Journal of Medicine, 2002
- Drug Interactions with Patient-Controlled AnalgesiaClinical Pharmacokinetics, 2002
- Drug Glucuronidation in Clinical PsychopharmacologyJournal of Clinical Psychopharmacology, 2001
- Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamideClinical Pharmacology & Therapeutics, 2001
- Concurrent Administration of the Erythromycin Breath Test (EBT) and Oral Midazolam as In Vivo Probes for CYP3A ActivityThe Journal of Clinical Pharmacology, 1999
- Adverse Drug Events in Hospitalized PatientsExcess Length of Stay, Extra Costs, and Attributable MortalityJAMA, 1997
- Drug-Related Morbidity and MortalityArchives of internal medicine (1960), 1995